MSK Report News

Thursday, November 05, 2009 News Analysis: Feds Set to Cut 21.5% from Medicare Fees—Before Healthcare Reform
The new Medicare Physician Fee Schedule will, overall, cut physician's fees by 21.5% in 2010...

Wednesday, November 04, 2009 Autoimmunity: Joan T. Merrill, MD, Answers Your Top Five Questions About Benlysta and Lupus
Benlysta™ (belimumab, formerly LymphoStat-B^®) is poised to be the first new lupus drug approved in 50 years...

Tuesday, November 03, 2009 ACR 2009: Naproxen/Nexium Combo Prevents Ulcers in OA Patients
Combining naproxen esomeprazole magnesium relieves OA pain while protecting the stomach...

Thursday, October 29, 2009 Autoimmunity: Uncertain Future for Schering RA Nose Spray
Intranasal immunotherapy with HC gp-39 was safe but produced no clinical benefits in a randomized, placebo-controlled phase II study in RA patients...

Thursday, October 29, 2009 ACR 2009: Bug Spray Linked to RA, Lupus
Startling new data from ACR suggest that household insecticide use increases women's risk of two autoimmune diseases...

Thursday, October 29, 2009 ACR 2009: Benlysta May Be the First New Lupus Drug in 50 Years
Benlysta™ (belimumab, formerly LymphoStat-B^®) is poised to be the first new lupus drug in 50 years...

Wednesday, October 28, 2009 BioPharm Business News and Perspectives: Third RA Patient Has PML After Rituximab
The FDA's MedWatch warning system reports that a third rheumatoid arthritis (RA) patient treated with Genentech's Rituxan (rituximab) has developed PML, this time without prior anti-TNF exposure...

Thursday, October 22, 2009 ACR 2009: For Early RA, Start with Six Months of MTX, then Add Two More DMARDs
ACR researchers report that initial treatment with methotrexate followed by step-up to two more DMARDs if needed at 6 months is as good as adding a TNF inhibitor...

Thursday, October 22, 2009 ACR 2009: Water, Skim Milk May Stave Off Gout Attacks
Encouraging gouty arthritis patients to drink more water and/or skim milk may lead to fewer gout attacks...

Wednesday, October 21, 2009 ACR 2009: Phase 2 Data Support Pfizer's JAK Inhibitor for RA
Two Phase 2 trials reported at ACR show efficacy of JAK inhibitor now in Phase 3...